TABLE 3.
Novel fusion partners of RET identified by DNA and RNA next‐generation sequencing
| Patient | Gender | Age, y | Cancer type | DNA_fusion | RNA_fusion |
|---|---|---|---|---|---|
| W002899T | Male | 41 | HCC | GABRG3‐RET_E5:E9 | GABRG3‐RET_E5:E9 |
| W027998T | Male | 62 | CRC | SNRNP70‐RET_E2:E12 | SNRNP70‐RET_E2:E12 |
| W001013T | Female | 46 | GC | OPALIN‐RET_E6:E11 | Negative |
| W016284T | Female | 61 | LC | KIF5B‐RET_E15:E12 | KIF5B‐RET_E15:E12 |
| GLI3‐RET_E2:E11 | GLI3‐RET_E2:E11 | ||||
| W044019T | Female | 33 | LC | KIF5B‐RET_E24:E9 | KIF5B‐RET_E24:E9 |
| MALRD1‐RET_E32:E8 | MALRD1‐RET_E32:E8 |
Abbreviations: CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; LC, lung cancer.